Yates Network News Today

CAMBRIDGE, Mass. & BRISBANE, Queensland, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced that the global

Funding from Wellcome will further broaden Vaxxas’ diverse clinical pipeline of next-generation vaccines to include Typhoid fever.Program will be jointly developed in collaboration with SK bioscience, a global leader in vaccine development.CAMBRIDGE, Mass. & BRISBANE, Queensland, Australia--(BUSINESS WIRE)--Vaxxas,...

NEW YORK--(BUSINESS WIRE)--Aug 23, 2023--

CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, today announced the opening of its

Industry veteran and senior medical leader from Pfizer brings deep global expertise as Vaxxas advances multiple clinical programs and moves toward commercialization.

CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced positive interim results from a

Phase 1 clinical trial advances with first subject dosed in the E.U. and IND accepted in the U.S. Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare

CEPI to provide up to USD4.3 million (AUD6.4 million) to Vaxxas to advance development of its high-density microarray patch for mRNA vaccines. Vaxxas' vaccine-delivery platform could improve access

Vaxxas to progress multiple vaccine programs in the clinic and ramp up manufacturing capabilities toward commercial scale.Equity funding to leverage non-dilutive financial support of more than US$67 million (A$100 million) which has been provided and committed under contracts with US and Australian government agenci...

CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced another key addition to its executive leadership team with the appointment of Doug Cubbin as Chief Financial Officer. Doug joins Vaxxas as the company...